This opportunity is now closed.

Funded PhD Opportunity

MicroRNA-based Therapeutics for Fibrosis in Glaucoma.

Subject: Biomedical Sciences


Summary

Glaucoma is a major cause of irreversible blindness, affecting more than 60 million people worldwide increasing to an estimated 79.6 million people by 2020. Primary open-angle glaucoma (POAG) is the commonest type of glaucoma and intraocular pressure (IOP) is an important modifiable risk factor. Elevated IOP in POAG is due to increased resistance to aqueous humour outflow and is the only treatable risk factor for glaucoma. Elevated IOP results from increased aqueous humour outflow resistance, a result of several morphologic and biochemical changes in the trabecular meshwork (TM); changes in the number of TM cells and the extracellular matrix (ECM) within the TM.  There is a large body of evidence that transforming growth factors - β1 and - β2 (TGF-β1 and -β2) play an important role in the pathogenesis of POAG. As well as playing a fundamental role in the pathogenesis of POAG by altering TM function and outflow facility and elevating IOP, TGFβ also has a deleterious effect on surgical outcomes for glaucoma causing post-operative scarring and surgical failure. MicroRNA (miRNA) based manipulation of the TGFβ signalling pathway is a new approach to target fibrosis following glaucoma surgery. MicroRNAs are small, non-coding RNAs which are important regulators of eukaryotic gene expression in most biological processes. miRNA-based therapeutics is an emerging field which is beginning to enter the clinical arena. In preliminary studies using genome-wide micro-arrays and small RNA-Seq we have identified miRNAs which are upregulated following TGFβ treatment of TM cells; we have termed ‘GlaucoMirs’. The specific impact of manipulating these ‘GlaucoMirs’ on the TGFβ signalling pathway could herald the generation of a new class of therapeutics for the medical and surgical management of glaucoma.

The aim of this studentship is to develop microRNA-based therapeutics to control fibrosis in glaucoma. A number of human and animal (porcine/bovine) cell and tissue models are available to support this project. We have an established ex vivo glaucoma perfusion model which the student will validate using porcine and/or bovine eye and utilise to perform microRNA manipulations to determine therapeutic endpoints. This ex vivo organ culture model which maintains the anterior segment of a pair of porcine/bovine eyes and glaucoma (raised IOP) is induced with TGFβ infusion in one eye; the untreated eye remains as control. miRNA mimics or inhibitors can be perfused to rescue IOP and downstream evaluation of mRNA, protein and structure can be evaluated directly in the TM. Drug delivery and efficacy can also be tested.

The specific objectives are: (1) Establish and validate a porcine and/or bovine glaucoma perfusion model. (2) Confirmation and identification of ‘GlaucoMirs’ using bioinformatics data mining and analyses combined with miRNA qPCR. (3) Experimental validation of miRNA targets. (4) Therapeutic manipulation of miRNAs as a phenotypic rescue to control fibrosis in glaucoma.


Essential criteria

  • Upper Second Class Honours (2:1) Degree or equivalent from a UK institution (or overseas award deemed to be equivalent via UK NARIC)
  • Sound understanding of subject area as evidenced by a comprehensive research proposal
  • A comprehensive and articulate personal statement

Desirable Criteria

If the University receives a large number of applicants for the project, the following desirable criteria may be applied to shortlist applicants for interview.

  • First Class Honours (1st) Degree
  • Completion of Masters at a level equivalent to commendation or distinction at Ulster
  • Research project completion within taught Masters degree or MRES
  • Experience using research methods or other approaches relevant to the subject domain
  • Work experience relevant to the proposed project
  • Publications - peer-reviewed
  • Experience of presentation of research findings

Funding

    The University offers the following awards to support PhD study and applications are invited from UK, EU and overseas for the following levels of support:

    Vice Chancellors Research Studentship (VCRS)

    Full award (full-time PhD fees + DfE level of maintenance grant + RTSG for 3 years).

    This scholarship will cover full-time PhD tuition fees and provide the recipient with £15,000 maintenance grant per annum for three years (subject to satisfactory academic performance). This scholarship also comes with £900 per annum for three years as a research training studentship grant (RTSG) allocation to help support the PhD researcher.

    Vice-Chancellor’s Research Bursary (VCRB)

    Part award (full-time PhD fees + 50% DfE level of maintenance grant + RTSG for 3 years).

    This scholarship will cover full-time PhD tuition fees and provide the recipient with £7,500 maintenance grant per annum for three years (subject to satisfactory academic performance). This scholarship also comes with £900 per annum for three years as a research training studentship grant (RTSG) allocation to help support the PhD researcher.

    Vice-Chancellor’s Research Fees Bursary (VCRFB)

    Fees only award (PhD fees + RTSG for 3 years).

    This scholarship will cover full-time PhD tuition fees for three years (subject to satisfactory academic performance). This scholarship also comes with £900 per annum for three years as a research training studentship grant (RTSG) allocation to help support the PhD researcher.

    Department for the Economy (DFE)

    The scholarship will cover tuition fees at the Home rate and a maintenance allowance of £ 15,009 per annum for three years. EU applicants will only be eligible for the fee’s component of the studentship (no maintenance award is provided). For Non-EU nationals the candidate must be "settled" in the UK. This scholarship also comes with £900 per annum for three years as a research training studentship grant (RTSG) allocation to help support the PhD researcher.

    Due consideration should be given to financing your studies; for further information on cost of living etc. please refer to: www.ulster.ac.uk/doctoralcollege/postgraduate-research/fees-and-funding/financing-your-studies


Other information


The Doctoral College at Ulster University


Reviews

My experience has been great and the people that I have worked with have been amazing

Kieran O'Donnell - 3D printing of biological cells for tissue engineering applications

Watch Video  

Completing the MRes provided me with a lot of different skills, particularly in research methods and lab skills.

Michelle Clements Clements - MRes - Life and Health Sciences

Watch Video  

Throughout my PhD I’ve been provided with continuous support and guidance by my supervisors and the staff at the University.I’ve also received many opportunities to further enhance my professional development in the form of teaching experience and presenting my work at conferences which will aid in my pursuit of a career in academia or industry.

William Crowe


Key dates

Submission deadline
Monday 19 February 2018

Interview Date
6, 7 and 8 March 2018


Applying

Apply Online  


Contact supervisor

Professor Tara Moore


Other supervisors

Related Funded Opportunities

Diabetes

Subject: Biomedical Sciences

 View details

Genomic Medicine

Subject: Biomedical Sciences

 View details

The regulation of rhamnolipid biosynthesis in Burkholderia thailandensis.

Closing date:
Tuesday 1 September 2020
Subject: Biomedical Sciences

 View details

Stratified Medicine

Subject: Biomedical Sciences

 View details

Optometry and Vision Science

Subject: Biomedical Sciences

 View details

MRes in Biomedical Sciences

Subject: Biomedical Sciences

 View details

The production of rhamnolipid biosurfactant by Pseudomonas aeruginosa growing in biofilms.

Closing date:
Tuesday 1 September 2020
Subject: Biomedical Sciences

 View details

Molecular Pathology of Glaucoma

Closing date:
Wednesday 1 January 2020
Subject: Biomedical Sciences

 View details

The design and analysis of a novel photo-activated antimicrobial system

Closing date:
Tuesday 1 September 2020
Subject: Biomedical Sciences

 View details